Actualizaciones regulatorias
16 sept 2026•3 min de lectura
FDA Approves ANDA203048 for Clindamycin Phosphate Injection by Rising
The FDA granted approval for Rising’s clindamycin phosphate injection products (6, 12, and 18 mg/mL) under application ANDA203048.
Actualizaciones regulatorias
15 sept 2026•3 min de lectura
FDA Grants Labeling Approval for Olmesartan Medoxomil Tablets (ANDA 078276)
FDA has approved labeling for oral Olmesartan Medoxomil tablets (5 mg, 20 mg, 40 mg) under ANDA 078276 submitted by Rising; the products are listed as discontinued.